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In their study, Ho et al1 report that using vaginal
progesterone gel twice daily for luteal support resulted
in better pregnancy outcomes than intramuscular prog-
esterone. Vaginal progesterone gel seemed to offer
more “targeted” delivery of progesterone to the uterus
and improved endometrial receptivity. The authors
also concluded that for patients with serum estradiol
levels on the day of human chorionic gonadotropin
greater than 5,000 pg/mL, vaginal gel still resulted in
better ongoing pregnancy and implantation rates.
In vitro fertilization (IVF) is a relatively new field
in medicine. Most of the individual studies in luteal
phase supplementation in IVF, excluding meta-analyses
which have their own limitations, lack adequate power
analysis to determine statistical significance, especially
if the study is a negative one.
Nevertheless, this study addressed the following
questions that are still in need of scientific investigation.
1. Should the dose of progesterone be dependent 
on peak estradiol level, the type of stimulation
protocol used, the age or the body weight of the
patient?
2. What is the optimal dose of progesterone, both
for vaginal gel and intramuscularly administrated
preparations (IMP)?
3. Would the protocol benefit from additional estra-
diol supplementation, what is the optimal dose of
estradiol, and when should it start and end?
4. When is the optimal time to start progesterone
supplementation? Before embryo transfer? And
when should it end?
The Importance of Progesterone in 
Early Pregnancy
A classic series of studies conducted more than 3 decades
ago demonstrated that progesterone secretion by the
corpus luteum (CL) is an absolute necessity for the
success of early human pregnancy. The success of early
pregnancy depends on progesterone that is primarily
from the corpus luteum before 7 weeks of gestation,
almost entirely from the trophoblast after 9 weeks of
gestation, and from both sources to varying extents in
the time between, which is known as the luteal-placental
shift. There are no reliable methods for diagnosing
progesterone deficiency during the luteal phase or early
pregnancy. Serum progesterone concentrations vary
widely during the mid and late luteal phases because
progesterone secretion by the corpus luteum is pul-
satile. Levels as low as 2.3 ng/mL and as high as
40.1 ng/mL have been observed within the relatively
short interval of time spanning a single secretory pulse
(60–90 minutes).2 Single and even serial serum prog-
esterone measurements have limited clinical utility and
may not provide a truly accurate gauge of the quality
of luteal function.
Role of the Endometrium and Embryo in
Human Implantation
The process of implantation requires a reciprocal
interaction between blastocyst and endometrium,
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culminating in a small window of opportunity during
which implantation can occur. Implantation itself is
governed by an array of endocrine, paracrine and
autocrine modulators of embryonic and maternal ori-
gin. Implantation failure is thought to occur as a con-
sequence of impairment of embryo developmental
potential and/or impairment of uterine receptivity
and the embryo-uterine dialogue. Progesterone and
estrogen are the dominant hormonal modulators of
endometrial development. Both the epithelial and stro-
mal compartments express progesterone and estrogen
receptors, and the response depends on the levels of
these receptors as well as on the concentration of the
hormones themselves. Although progesterone and
estrogen are the key modulators of endometrial mat-
uration, their roles in this process are complex and
sophisticated. Hormonal activity depends not only on
the levels of progesterone, estrogen and their recep-
tors, but also on the rates of progesterone and estrogen
metabolism. The activities of progesterone and estro-
gen are also influenced by the effects of co-activators
and repressors. Furthermore, both hormones regu-
late the expression of numerous endometrial proteins.
In addition to progesterone and estrogen, a number
of other endocrinologic factors are known to mediate
endometrial function.3 By understanding the activity
and function of the hormones and factors involved in
this dialogue, it may be possible to use them as predic-
tors of endometrial receptivity or embryo quality to
maximize implantation rates in hormonally stimulated
assisted reproductive technology (ART) cycles.
Rationale for Hormonal Supplementation
with Progesterone in Stimulated 
IVF Cycles
In stimulated cycles typical of IVF therapy, the luteal
phase is different from the natural one in 2 important
ways. First, since ovarian stimulation produces multi-
ple corpora lutea, the levels of both estradiol and
progesterone in the early part of the luteal phase are
supraphysiological. Second, and perhaps more impor-
tantly, the duration of ovarian steroid production in
stimulated cycles is usually shorter than normal by
1–3 days. This truncated luteal phase has been noted
since the earliest days of IVF and created concern that
an early menses might prevent successful implantation
since menses were on occasion observed to occur as
early as 10 days after egg retrieval.4
In stimulated IVF cycles, the use of gonadotropin-
releasing hormone (GnRH) agonists and the removal
of granulosa cells during aspiration of the oocyte can
lead to a relative progesterone deficit and inappropriate
preparation of the endometrium for embryo implan-
tation and survival of the pregnancy. The use of GnRH
agonists in ovarian stimulation, which prevents a pre-
mature surge of luteinizing hormone (LH), ultimately
leads to suppression of the pituitary gland, thereby
blocking the secretion of LH for at least 10 days fol-
lowing the last applied GnRH dose, as well as the pul-
satile secretion of progesterone. In addition, high levels
of estrogen observed during stimulated cycles result
in an inhibitory effect on the implantation of human
embryos. The use of pharmaceutical luteal support to
reach the physiologic ratio of estrogen to progesterone
could only be beneficial.5
Timing of Luteal Support and When It
Should End
Mochtar et al, in a 3-armed randomized prospective
study with patients on a GnRH agonist suppression
protocol, reported no significant differences in ongo-
ing pregnancy rate when micronized vaginal proges-
terone was started the day after human chorionic
gonadotropin (hCG) administration, the day of oocyte
retrieval, or the day of embryo transfer. We can con-
clude that most IVF clinicians start supplementation
after oocyte retrieval and before embryo transfer, but
the optimal time, if there is one, is still not known.6
Andersen et al, in a prospective and randomized
study, substantiated the other studies and reported no
difference in the delivery rate between pregnant patients
who discontinued progesterone when the patient had
a positive pregnancy test and those who continued it
until 7 weeks of gestation. All of the prior studies in-
cluded a relatively large number (180–400) of patients.
As such, we can conclude that there is no strong evi-
dence in the literature that supports continuation of
supplementation beyond the first positive hCG result.7
However, most clinicians empirically continue
supplementation through to about 10 weeks of gesta-
tion (or 8 weeks from egg retrieval).
Route of Progesterone Administration
for Luteal Support
Possible routes of progesterone delivery include trans-
dermal, oral, intramuscular, transvaginal, sublingual,
nasal, and rectal. Only 3 routes of support—oral,
intramuscular, and transvaginal—have been widely
used, and only 2—intramuscular and transvaginal—
are satisfactory methods at this time.
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There is special need for luteal support in con-
trolled ovarian hyperstimulation induced for IVF–
embryo transfer (IVF-ET), particularly when GnRH
agonists are used. This support can be achieved either
by repeated hCG injections or by progesterone sup-
plementation. The latter option has been universally
preferred since it has become evident that hCG injec-
tions increase the risk of frank ovarian hyperstimulation
syndrome (OHSS).
Progesterone administered orally is extensively
degraded by hepatic first-pass metabolism and the
serum level typically returns to baseline level by 6
hours, which makes this route inefficient for luteal
support. Therefore, progesterone should be adminis-
tered only non-orally to support endometrial recep-
tivity in infertility treatments. Although intramuscular
administration is effective, clinicians have pursued a
vaginal alternative in an attempt to avoid painful intra-
muscular injections.
In the US, the first FDA-approved system for
pregnancy support was Crinone 8% (Fleet Laboratories
Ltd., Hertfordshire, UK). It is a bioadhesive vaginal
gel that contains 90 mg of micronized progesterone
in an emulsion system designed to adhere to the vagi-
nal mucosa and thus achieve controlled and sustained
delivery. The advantages of Crinone over other vagi-
nal therapies are a longer half-life and lower patient-
to-patient variability in absorption. Crinone 8% applied
once to twice a day provides progesterone directly to
the endometrium through a first-uterine-pass effect.
The serum level remains elevated for up to 48 hours.
Further, Jobanputra et al, in a donor-egg IVF study,
showed that 100% “in-phase” endometrial biopsies,
reassuring pregnancy rates (46–48% vs. 41%) and mis-
carriage rates (14–33% vs. 25%) were seen at both the
twice and once-daily dosing levels compared to intra-
muscular therapy. Pregnancy rates were as high with
vaginal as with intramuscular therapy. There were no
significant differences in clinical pregnancy and implan-
tation rate using twice-daily Crinone or once-daily
Crinone.8 Khan et al, in a case-matched comparison
of Crinone 8% and IMP demonstrated similar preg-
nancy, miscarriage, and live birth rates.9 However,
there are other studies that have shown that women
who received IMP had higher ongoing pregnancy
and live birth rates per transfer.10
Ho et al1 found that the vaginal gel group compared
with the IMP group had lower mid-luteal serum prog-
esterone levels but higher implantation rate (32.5% vs.
18.5%) and ongoing pregnancy rate (55.2% vs. 32.5%).
However, the retrospective nature of the study, with
its associated biases, as well as the potential impact of
other confounding variables (e.g. presence or absence
of uterine factors, embryo scorings, etc. was equal
across studied groups) limit their outcomes. The authors
should provide results for ongoing pregnancy—
defined as a viable pregnancy confirmed at 20 weeks
of gestation, rather than just a viable fetus at 12 weeks
of gestation, because the occurrence of a few early
pregnancy losses might have significantly altered the
reported outcomes.
The Optimal Dose of Progesterone
Supplementation of the luteal phase in IVF started
empirically, and unfortunately, the data are limited
with regard to the best dose. Few randomized trials
have been performed to compare dosages and formu-
lations. No differences were observed in clinical preg-
nancy rates.8 As such, there is definitely a need for more
randomized controlled trials to assess the effective-
ness of different doses for the different progesterone
formulations. However, Ho et al, in their retrospective
study, only compared twice-daily Crinone with IMP.
Addition of Estradiol to Progesterone in
IVF Cycle
The implantation process depends on the quality of
the endometrium, which is affected by both estradiol
and progesterone. During the follicular phase, it is
mainly dependent on estradiol. The role of estradiol
during the luteal phase is unclear. However, in IVF
cycles, the levels of estradiol and progesterone drop in
the mid to late luteal phase.
Farhi et al evaluated the effect of adding 2 mg of
estradiol orally twice a day to 50 mg intramuscular
injection of progesterone and 50 mg vaginal proges-
terone twice a day. The estradiol supplementation was
started on day 7 after embryo transfer. The study
included women who were felt to be at risk of OHSS
and who were not candidates for hCG luteal phase
supplementation (estradiol>2,500 pg/mL on the day
of hCG trigger). A higher pregnancy rate was observed
in women who received estradiol and long GnRH
agonist protocols (39.6% vs. 25.6%, p <0.05).11
Lukaszuk et al conducted a randomized prospec-
tive study on the dose of micronized estradiol needed in
patients on the long GnRH agonist protocol. Patients
were randomized to receive no estradiol, 2 mg, or 6 mg
of micronized estradiol, in addition to 200 mg three
times daily of vaginal micronized progesterone. In
the trial, estradiol was started on the day of oocyte
retrieval. The addition of estradiol during the luteal
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phase resulted in an increase in implantation and
pregnancy rates. The pregnancy rate was 51.3% in
women who received the high estradiol dose (6 mg),
whereas it was 32.8% in those on the 2 mg dose, and
only 23.1% in the no estradiol group. Multiple preg-
nancies were also statistically significantly higher in
women who received estradiol. The rates of sponta-
neous abortions and ectopic pregnancies were similar
in all 3 groups.12
The cycles were suppressed with a mid-luteal
GnRH agonist protocol. Similarly, Tay and Lenton13
did not find an advantage in the clinical pregnancy
rate when oral estradiol valerate (2 mg) and 400 mg
of micronized progesterone applied vaginally were
compared with progesterone alone. In 1 prospective
study, 600 mg of micronized vaginal progesterone
once daily was compared with the combination of
vaginal progesterone and 6 mg of estradiol valerate.
The clinical pregnancy rates were similar.14
In a more recent trial in which a GnRH antagonist
was used, patients were randomized to receive proges-
terone alone or progesterone and estradiol during the
luteal phase. All women received 200mg of micronized
progesterone vaginally 3 times daily. One group also
received 2 mg of estradiol valerate orally twice a day.
Both progesterone and estradiol were started the day
after oocyte retrieval. The endocrine profile (follicle-
stimulating hormone, LH, estradiol, progesterone) was
similar in both groups, and the investigators concluded
that the addition of estradiol in GnRH antagonist
cycles was unlikely to affect pregnancy rates.15
Supplementing with Progesterone Alone
and/or hCG in IVF Cycles
Luteal support is most commonly provided by treat-
ment with supplemental progesterone but can also be
achieved effectively by the administration of exoge-
nous hCG. In IVF cycles involving treatment with a
long-acting GnRH agonist, hCG stimulation of luteal
function and progesterone supplementation have sim-
ilar effectiveness. In an analysis of combined data from
6 clinical trials involving a total of 1,038 women, the
ongoing pregnancy rate per embryo transfer in cycles
supplemented directly with progesterone was not sig-
nificantly different from that in cycles supplemented
with hCG (odds ratio, 0.94; 95% confidence interval,
0.70–1.27).8 However, the risk for OHSS was signi-
ficantly lower in women who received progesterone
supplementation than for those who were treated
with hCG (odds ratio, 0.46; 95% confidence interval,
0.26–0.81).16
Summary and Recommendations
Luteal-phase supplementation in IVF stimulated cycles
is a well-established practice that will continue in the
future. Success rates are similar with intramuscular
and vaginal administration, with patient preference
for the vaginal route. Pregnancy rates are also similar
for different forms of vaginal progesterone.
Currently, there is no reliable method for the spe-
cific diagnosis of progesterone deficiency during the
luteal phase of the menstrual cycle or early pregnancy.
In IVF cycles involving downregulation with a
long-acting GnRH agonist, progesterone supplemen-
tation (50 mg/day administered intramuscularly, or
Crinone 8%, 90 mg/day, administered vaginally) yields
significantly higher pregnancy rates when compared
with treatment with placebo or no treatment.
Luteal-phase supplementation with hCG is associ-
ated with greater risk of OHSS compared with supple-
mentation with progesterone.
Luteal-phase supplementation in IVF stimulated
cycles is considered to be an essential requirement for
optimal success.
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